keyword
MENU ▼
Read by QxMD icon Read
search

Treatment for drug reaction causing ILD

keyword
https://www.readbyqxmd.com/read/26112359/granulomatous-reaction-to-pneumocystis-jirovecii-diagnosed-in-a-bronchoalveolar-lavage-a-case-report
#1
Antoine Nobile, Antonio Valenti, John-David Aubert, Catherine Beigelman, Igor Letovanec, Massimo Bongiovanni
BACKGROUND: Granulomatous reaction to Pneumocystis jirovecii is a rare but well-known pathological finding encountered in the setting of immunosuppression, HIV infection being the most common cause. It can also potentially complicate the treatment of hematological malignancies, typically when drugs lowering the count and function of lymphocytes are used. Lung biopsy is considered the gold standard for the diagnosis of granulomatous P. jirovecii pneumonia, whereas the diffuse alveolar form is usually detected cytologically in bronchoalveolar lavage (BAL)...
2015: Acta Cytologica
https://www.readbyqxmd.com/read/25761482/gefitinib-induced-interstitial-lung-disease-in-korean-lung-cancer-patients
#2
Seung-Hoon Beom, Dong-Wan Kim, Sung Hoon Sim, Bhumsuk Keam, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo
PURPOSE: Interstitial lung disease (ILD) is a serious adverse effect of gefitinib. We examined the incidence and clinical characteristics of drug-induced ILD in Korean non-small cell lung carcinoma patients treated with gefitinib. MATERIALS AND METHODS: A retrospective cohort study was performed in non-small cell lung cancer (NSCLC) patients who started gefitinib treatment at Seoul National University Hospital from January 2002 through December 2011. Patients who developed new abnormal radiologic findings with respiratory symptoms after gefitinib treatment were defined as having possible adverse pulmonary reactions...
January 2016: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/24668537/rheumatoid-arthritis-and-lung-disease-from-mechanisms-to-a-practical-approach
#3
REVIEW
Fiona Lake, Susanna Proudman
Rheumatoid arthritis (RA) is a common chronic systemic autoimmune disease characterized by joint inflammation and, in a proportion of patients, extra-articular manifestations (EAM). Lung disease, either as an EAM of the disease, related to the drug therapy for RA, or related to comorbid conditions, is the second commonest cause of mortality. All areas of the lung including the pleura, airways, parenchyma, and vasculature may be involved, with interstitial and pleural disease and infection being the most common problems...
April 2014: Seminars in Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/23152005/current-status-of-dild-in-molecular-targeted-therapies
#4
REVIEW
Yoshinobu Saito, Akihiko Gemma
Molecular targeted drugs have become the mainstream for cancer therapy, and they have contributed to improving the outcome for cancer patients. On the other hand, molecular targeted drugs are associated with a variety of adverse drug reactions. Drug-induced interstitial lung disease (DILD) is a typical adverse drug reaction that has been an important problem with regard to safety management during cancer treatment. In the past, there was a lack of detailed and accurate epidemiological data about DILD. However, most of the molecular targeted drugs have been subject to all-case post-marketing surveillance since gefitinib-induced ILD became a concern...
December 2012: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/22779302/nitrofurantoin-induced-immune-mediated-lung-and-liver-disease
#5
Rade Milić, Goran Plavec, Ivana Tufegdzić, Ilija Tomić, Sanja Sarac, Olivera Loncarević
INTRODUCTION: Nitrofurantoin, a furan derivative, introduced in the fifties has widely been used as an effective agent for the treatment and prevention of urinary tract infections (UTI). Spectrum of adverse reactions to nitrofurantoin is wide, ranging from eosinophilic interstitial lung disease, acute hepatitis and granulomatous reaction, to the chronic active hepatitis, a very rare adverse effect, that can lead to cirrhosis and death. CASE REPORT: We presented a 55-year- old female patient with eosinophilic interstitial lung disease, severe chronic active hepatitis and several other immune- mediated multisystemic manifestations of prolonged exposure to nitrofurantoin because of the recurrent UTI caused by Escherichia coli...
June 2012: Vojnosanitetski Pregled. Military-medical and Pharmaceutical Review
https://www.readbyqxmd.com/read/22317852/are-high-doses-of-prednisone-necessary-for-treatment-of-interstitial-lung-disease-in-systemic-sclerosis
#6
RANDOMIZED CONTROLLED TRIAL
Dionisio Pérez Campos, Miguel Estévez Del Toro, Aisa Peña Casanovas, Pedro Pablo González Rojas, Lisvenia Morales Sánchez, Angela Rosa Gutiérrez Rojas
INTRODUCTION: Interstitial lung disease (ILD) as part of systemic sclerosis (SS) is a leading cause of morbidity and mortality. OBJECTIVES: To evaluate the use of intravenous pulse cyclophosphamide combined with low and high doses of prednisone in the treatment of ILD in SS is equally effective. METHOD: An experimental, exploratory and randomized single-blind clinical trial was conducted at Hermanos Ameijeiras Clinical Surgical Hospital from September 2006 to December 2009, including 23 patients with SS and ILD...
March 2012: Reumatología Clinica
https://www.readbyqxmd.com/read/20634671/interstitial-lung-disease-associated-with-azacitidine-use-a-case-report
#7
Arunabh Sekhri, Chandrasekar Palaniswamy, Kusuma Kurmayagari, Ankur Kalra, Dhana R Selvaraj
Azacitidine is a pyrimidine nucleoside analog licensed for treatment of adult patients with myelodysplastic syndrome. Azacitidine acts as an inducer of cell differentiation by causing demethylation and re-expression of genes silenced by hypermethylation. We report a 56-year-old man with myelodysplastic syndrome who developed interstitial lung disease after azacitidine therapy. Open lung biopsy revealed a nonresolving organizing pneumonia pattern and bronchocentric granulomatous pattern suggestive of drug-induced lung injury...
March 2012: American Journal of Therapeutics
https://www.readbyqxmd.com/read/20180616/lenalidomide-induced-interstitial-lung-disease
#8
Yijia Chen, Porntip Kiatsimkul, Kenneth Nugent, Rishi Raj
Lenalidomide is a more potent and less toxic oral analog of thalidomide. The drug is indicated for treatment of multiple myeloma and other hematologic disorders and has rarely been associated with pulmonary toxicity. We describe a 73-year-old woman who received lenalidomide therapy for multiple myeloma. Nine weeks after starting the drug, she developed progressive dyspnea, cough, and constitutional symptoms, and was found to be hypoxic. A computed tomography scan of the chest showed bilateral interstitial infiltrates...
March 2010: Pharmacotherapy
https://www.readbyqxmd.com/read/19387736/intravenous-immunoglobulin-therapy-for-refractory-interstitial-lung-disease-associated-with-polymyositis-dermatomyositis
#9
Yuzo Suzuki, Hiroshi Hayakawa, Seiichi Miwa, Masahiro Shirai, Masato Fujii, Hitoshi Gemma, Takafumi Suda, Kingo Chida
Interstitial lung disease (ILD) associated with polymyositis/dermatomyositis (ILD-PM/DM), including amyopathic dermatomyositis (ADM), is recognized as an important condition because it frequently causes death, despite intensive therapy with high-dose corticosteroid and immunosuppressive agents, such as cyclosporine A and cyclophosphamide. Intravenous immunoglobulin therapy (IVIG) has shown efficacy for myopathy associated with PM/DM, but its usefulness for ILD-PM/DM is unclear. This study was designed to investigate the efficacy of IVIG for refractory ILD-PM/DM...
May 2009: Lung
https://www.readbyqxmd.com/read/17940494/relevance-of-pharmacogenetic-aspects-of-mercaptopurine-metabolism-in-the-treatment-of-interstitial-lung-disease
#10
REVIEW
Jaap A Bakker, Marjolein Drent, Jörgen Bierau
PURPOSE OF REVIEW: Mercaptopurine therapy is increasingly important as immunosuppressive therapy in interstitial lung disease. We focus on human mercaptopurine metabolism and the defects in this metabolism causing adverse drug reactions. RECENT FINDINGS: Defects in mercaptopurine metabolizing enzymes like thiopurine methyltransferase and inosine triphosphate pyrophosphohydrolase lead to severe adverse drug reactions, sometimes with fatal outcome. Other enzymes, still not thoroughly investigated, can give rise to toxic effects or decreased efficacy in mercaptopurine therapy when the activity of these enzymes is altered...
September 2007: Current Opinion in Pulmonary Medicine
https://www.readbyqxmd.com/read/11465077/recent-advances-in-particulate-induced-pulmonary-fibrosis-for-the-application-of-possible-strategy-experimentally-and-clinically
#11
REVIEW
K A Kim, C Y Park, Y Lim, K H Lee
Chronic interstitial lung diseases including pneumoconiosis have pathological characteristics which alter the lung structure and function consequent to the accumulation and activation of inflammatory cells in the lower respiratory tract. These activated cells usually secrete the inflammatory and fibrogenic mediators. Of the diffuse parenchymal lung diseases, the majority have no known etiology and idiopathic pulmonary fibrosis (IPF) is the diagnosis most frequently encountered by clinicians. Pathogenic similarities between pneumoconiosis and IPF provide a strong basis for hypothesizing that environmental agents may cause IPF...
November 2000: Current Drug Targets
https://www.readbyqxmd.com/read/11247879/mri-guided-muscle-biopsy-confirmed-polymyositis-diagnosis-in-a-patient-with-interstitial-lung-disease
#12
J Lampa, I Nennesmo, H Einarsdottir, I Lundberg
UNLABELLED: Idiopathic inflammatory myopathies, such as polymyositis (PM), may present with general symptoms such as fever and fatigue and only minimal muscle weakness, making it difficult to make a definite diagnosis and provide adequate treatment. Here a case is described in which interstitial lung disease was the first and most prominent manifestation of PM. Later, when muscle weakness became apparent and inflammatory muscle disease was suspected the first muscle biopsy was non-diagnostic...
April 2001: Annals of the Rheumatic Diseases
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"